Intuitive Surgical vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Robotic surgery pioneer with 9,800+ da Vinci systems; da Vinci 5 adds haptic feedback; $8.35B FY2024 revenue; 57,000+ trained surgeons create switching costs; J&J and Medtronic competing.
About
Intuitive Surgical is the global pioneer and dominant leader in robotic-assisted minimally invasive surgery, founded in 1995 and headquartered in Sunnyvale, California. The company trades on Nasdaq (ISRG) and reported $8.35 billion in FY2024 revenue, representing approximately 17% year-over-year growth, with an installed base of nearly 9,800 da Vinci surgical systems deployed in hospitals across 70+ countries. The fourth-generation da Vinci 5 system—launched in 2024—introduced haptic force feedback for the first time, allowing surgeons to sense tissue resistance through robotic instruments, a breakthrough that strengthens Intuitive's technical moat and accelerates system upgrades among existing customers.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.